A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal

被引：0
|
作者：
R. F. Anton
Henry R. Kranzler
Joseph P. McEvoy
Darlene H. Moak
Ralph Bianca
机构：
[1] Medical University of South Carolina,
[2] Institute of Psychiatry,undefined
[3] 171 Ashley Avenue,undefined
[4] Charleston,undefined
[5] SC 29425,undefined
[6] USA,undefined
[7] Department of Psychiatry,undefined
[8] University of Connecticut Health Center,undefined
[9] 263 Farmington Avenue,undefined
[10] Farmington,undefined
[11] CT 06032–1956,undefined
[12] USA,undefined
[13] John Umstead Hospital,undefined
[14] Clinical Research Program,undefined
[15] Box 31,undefined
[16] Butner,undefined
[17] NC 27509,undefined
[18] USA,undefined
[19] Sandoz Pharmaceuticals,undefined
[20] 59 Route 10,undefined
[21] East Hanover,undefined
[22] NJ 07936–1080,undefined
[23] USA,undefined
来源：
Psychopharmacology | 1997年 / 131卷
关键词：
Key words Alcohol withdrawal; Treatment; Abecarnil; Partial benzodiazepine agonists;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment of the alcohol withdrawal syndrome is best accomplished using pharmacologic agents that have minimal interaction with alcohol, have limited adverse effects, and are without abuse potential. The partial benzodiazepine receptor agonist beta-carboline compound, abecarnil, has been shown in animal and human studies to possess a number of these characteristics and to be useful in the reduction of alcohol withdrawal convulsions in mice. In this study, 49 alcohol-dependent inpatients who exhibited at least moderate symptoms of uncomplicated alcohol withdrawal were treated over a 5-day detoxification period with abecarnil or diazepam and rated daily for alcohol withdrawal symptoms and adverse events. Both the abecarnil and diazepam treatment groups exhibited a similar marked reduction in withdrawal symptoms over time. In addition, similar rates of successful treatment and improvement were observed after 1 day of treatment and at termination in alcoholics treated with either medication. Overall, rates of adverse events and changes in liver enzymes were similar in both treatment groups and were generally benign. Because of the unique pharmacologic profile of abecarnil in animal and in non-clinical human studies, including anticonvulsant action, low abuse liability, and a favorable side effect profile, further study of compounds of the partial benzodiazepine receptor agonist type in the treatment of alcohol withdrawal syndromes seems warranted.
引用
收藏
页码：123 / 129
页数：6
相关论文
共 50 条
12345